- Home
- ENTX vs CRVO Comparison
ENTX vs CRVO Comparison
Compare ENTX & CRVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ENTX
- CRVO
- Stock Information
- Founded
- ENTX 2010
- CRVO 2001
- Country
- ENTX Israel
- CRVO United States
- Employees
- ENTX N/A
- CRVO N/A
- Industry
- ENTX Biotechnology: Biological Products (No Diagnostic Substances)
- CRVO Biotechnology: Pharmaceutical Preparations
- Sector
- ENTX Health Care
- CRVO Health Care
- Exchange
- ENTX Nasdaq
- CRVO Nasdaq
- Market Cap
- ENTX 90.2M
- CRVO 98.3M
- IPO Year
- ENTX 2018
- CRVO N/A
- Fundamental
- Price
- ENTX $2.10
- CRVO $2.28
- Analyst Decision
- ENTX Strong Buy
- CRVO Buy
- Analyst Count
- ENTX 1
- CRVO 8
- Target Price
- ENTX $10.00
- CRVO $33.00
- AVG Volume (30 Days)
- ENTX 70.9K
- CRVO 98.9K
- Earning Date
- ENTX 03-07-2025
- CRVO 03-31-2025
- Dividend Yield
- ENTX N/A
- CRVO N/A
- EPS Growth
- ENTX N/A
- CRVO N/A
- EPS
- ENTX N/A
- CRVO N/A
- Revenue
- ENTX $99,000.00
- CRVO $10,066,550.00
- Revenue This Year
- ENTX N/A
- CRVO $34.17
- Revenue Next Year
- ENTX N/A
- CRVO N/A
- P/E Ratio
- ENTX N/A
- CRVO N/A
- Revenue Growth
- ENTX 607.14
- CRVO 116.29
- 52 Week Low
- ENTX $1.00
- CRVO $1.80
- 52 Week High
- ENTX $3.35
- CRVO $26.38
- Technical
- Relative Strength Index (RSI)
- ENTX 40.77
- CRVO 41.42
- Support Level
- ENTX $2.20
- CRVO $2.14
- Resistance Level
- ENTX $2.49
- CRVO $2.37
- Average True Range (ATR)
- ENTX 0.22
- CRVO 0.14
- MACD
- ENTX -0.03
- CRVO 0.09
- Stochastic Oscillator
- ENTX 16.13
- CRVO 56.41
About ENTX Entera Bio Ltd.
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to significantly shift a treatment paradigm. Its product candidates are; EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are first-in-class mini tablet formulations of synthetic human PTH (1-34) (teriparatide), designed to have differing pharmacokinetic, or PK, profiles.
About CRVO CervoMed Inc.
CervoMed Inc is a clinical-stage biotechnology company. It is focused on developing treatments for age-related neurologic disorders. The company's product candidate, Neflamapimod has the potential to treat and improve synaptic dysfunction, the reversible aspect of the underlying disease processes in DLB and certain other neurological disorders.